Business
Result of Extraordinary General Meeting
4basebio PLC announced that all resolutions proposed at its Extraordinary General Meeting held on October 10, 2025, were duly passed. Disclaimer*
About this update from 4basebio Plc
10 October 2025 4basebio PLC ("4basebio" or the "Company") Result of Extraordinary General Meeting Cambridge, UK, 10 October 2025 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform announces that all of the resolutions proposed at its Extraordinary General Meeting held earlier today were duly passed. For further enquiries, please contact: 4basebio PLC +44 (0)12 2396 7943 Dr. Heikki Lanckriet, CEO Cairn Financial Advisers LLP (Nominated Adviser ) +44 (0)20 7213 0880 Jo Turner / Sandy Jamieson / Ed Downes Cavendish Capital Markets Limited ( Joint Broker) +44 (0)20 7220 0500 Geoff Nash / Nigel Birks RBC Capital Markets (Joint Broker) +44 (0) 20 7653 4000 Kathryn Deegan / Matthew Coakes Notes to Editors About 4basebio 4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.